Hepatitis B Virus (HBV)

Atorvastatin calcium: EFFICACY(1)

Atorvastatin calcium: EFFICACY(1)Placebo controlled, dose-response studies

In two multicentre, placebo controlled, double-blind, dose-response studies of six weeks’ duration, conducted in patients with mild to moderate hypercholesterolemia, atorvastatin 10 to 80 mg administered once-daily resulted in dose-dependent reductions of elevated levels of total cholesterol, LDL-C, triglyceride and apo B compared with placebo . HDL-C levels were modestly increased. LDL-C reductions ranged from 39% to 60%, and triglyceride reductions ranged from 19% to 37% over the dose range of 10 to 80 mg (Table 1). Cheapest online shopping – find at best fully-licensed pharmacy.


Dose-response in double-blind, placebo controlled studies in patients with mild to moderate hypercholesterolemia (mean percentage change from baseline)

Atorvastatin dose (mg/day) n Total-C LDL-C TG HDL-C Apo B
Placebo 21 +4 +4 +10 -3 +3
10 22 -29 -39 -19 +6 -32
20 20 -33 -43 -26 +9 -35
40 21 -37 -50 -29 +6 -42
80 23 -45 -60 -37 +5 -50

Results are pooled data from two dose-response studies. Based on data from references 39, 47and 48. Apo B Apolipoprotein B; HDL-C High density lipoprotein cholesterol; LDL-C Low density lipoprotein cholesterol; TG Triglyceride; Total-C Total cholesterol. Reprinted by permission from Pharmaceuticals and Specialties, 33rd edn, page 889, published by the Canadian Pharmacists Association, Ottawa, copyright 1998

At each dose, approximately 90% of the LDL-C reduction was observed within two weeks of treatment, and the maximum response was usually achieved within two to four weeks . In another placebo controlled, six-month study, 96% to 98% of the maximum reductions in LDL-C, total cholesterol and apo B were obtained within four weeks of beginning treatment and were maintained for the duration of the study . The effect on triglyceride levels was, however, more time-dependent, with a gradual increase over the entire six-month period.

Category: Calcium

Tags: Atorvastatin, Coronary artery disease, Dyslipidemia, HMG-CoA reductase inhibitors, Hypercholesterolemia, Statins

Leave a Reply

Your email address will not be published. Required fields are marked *